Provention Bio, Inc.
(NASDAQ : PRVB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.27%139.720.7%$1069.68m
PFEPfizer Inc.
-0.27%42.650.9%$908.26m
MRKMerck & Co., Inc.
0.30%83.030.6%$730.47m
BMYBristol-Myers Squibb Company
1.56%48.301.4%$540.03m
LLYEli Lilly and Company
0.61%112.421.0%$476.52m
ABBVAbbVie, Inc.
0.18%78.832.2%$356.97m
NVSNovartis AG Sponsored ADR
0.47%89.940.2%$198.93m
AZNAstraZeneca PLC Sponsored ADR
0.38%39.821.2%$111.75m
GSKGlaxoSmithKline plc Sponsored ADR
-0.42%39.950.2%$88.77m
NVONovo Nordisk A/S Sponsored ADR Class B
0.68%51.310.1%$74.03m
SNYSanofi Sponsored ADR
-0.02%42.460.2%$73.11m
LCILannett Company, Inc.
2.49%5.3536.6%$4.83m
AKTXAkari Therapeutics Plc Sponsored ADR
0.85%2.261.6%$0.37m
EPIXESSA Pharma Inc
0.88%2.300.1%$0.02m

Company Profile

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.